Trials / Withdrawn
WithdrawnNCT04096573
Efficacy and Safety of LC51-0255 in Subjects With Ulcerative Colitis
A Phase 2, Multi Center, Randomized, Placebo Controlled Parallel Group Study to Evaluate the Clinical Efficacy and Safety of LC51 0255 in Subjects With Moderately to Severely Active Ulcerative Colitis
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- LG Chem · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2, multi center, randomized, placebo controlled parallel group study to evaluate the clinical efficacy and safety of LC51 0255 in subjects with moderately to severely active ulcerative colitis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LC51-0255 | LC51-0255 |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2020-04-01
- Primary completion
- 2021-11-01
- Completion
- 2022-08-01
- First posted
- 2019-09-20
- Last updated
- 2021-11-15
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04096573. Inclusion in this directory is not an endorsement.